Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea.
Hyun Deok ShinIl Han SongSae Hwan LeeHong Soo KimTae Hee LeeHyuk Soo EunSeok Hyun KimByung Seok LeeHee Bok ChaeSeok Hwan KimMyung Joon SongSoon Yeong KoSuk Bae KimPublished in: The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi (2024)
Both regimens had similar treatment completion rates, effectiveness, and safety profiles. Therefore, the SOF/LDV regimen can also be considered a viable DAA for the treatment of patients with genotype 1 or 2 chronic hepatitis C.